With an experienced researcher at the helm, Seoul-based Theragen Bio aims to leverage its sequencing and bioinformatics expertise to also develop cancer therapies
London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting
London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections
Seoul based ABL Bio is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well
Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea
London Healthcare Week: A discussion on treating neurodegenerative diseases with the CEO of AC Immune
London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space
The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta
From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi
Visiting the largest cell therapy company in Korea, GC Cell, and learning about its approved immunotherapy for hepatocellular carcinoma, its CAR-NK programs in development, and more
London Healthcare Week: After announcing FIH data from its oral GLP in obesity in September, Terns is also getting ready to release initial data in December for its allosteric BCR ABL cancer program
London Healthcare Week: Forbion Managing Partner Sander Slootweg shares his thoughts on the year ahead, the IPO market, M&A environment, areas of interest, and more
The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP
From Seoul: AimedBio is leveraging patient data and its expertise in antibody discovery and design to develop first-in-class antibody-drug conjugates with unique targets - the first program is FGFR3
From Seoul: Kicking off BiotechTV's one week visit to Korea by getting an overview of the growth and current state of biotech in the country from KoreaBIO
London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings
London Healthcare Week: Rinri Therapeutics is working on a hearing loss solution that uses stems cells that are turned into the precursors of auditory neurons, cells that cannot naturally regenerate
A patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trial
London Healthcare Week: Oculis is aiming to redefine ophthalmology through methods like an eye drop technology that can reach the back of the eye and precision medicine like patient selection
London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year
.png){kind=logo}
